Join Growin Stock Community!

訊聯1784.TW Overview

TW StockBiotech. & Medical
(No presentation for 1784)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

訊聯(1784)Overall Performance

訊聯(1784)AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

訊聯(1784) PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

訊聯(1784)Key Information

訊聯(1784)Profile

BIONET Corp. provides cord blood banking services in Taiwan and internationally. The company offers stem cell banking services, including stem cell storage, mesenchymal stem cell storage, dental stem cell storage, adipose stem cell, and PBSC + immune cells; and genetic testing services. It also provides stem anti-aging and ANIKINE series products. In addition, the company offers Exosome, a novel cell-free therapy. The company was founded in 1989 and is based in Taipei City, Taiwan.

訊聯(1784)FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
43.77
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
55.71%
Net Margin
5.71%
Revenue Growth (YoY)
3.76%
Profit Growth (YoY)
5.06%
3-Year Revenue Growth
6.55%
3-Year Profit Growth
4.21%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
43.77
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
55.71%
Net Margin
5.71%
Revenue Growth (YoY)
3.76%
Profit Growth (YoY)
5.06%
3-Year Revenue Growth
6.55%
3-Year Profit Growth
4.21%
default symbol

1784

訊聯

99.80D

-4.21%

(-0.04)

  • When is 1784's latest earnings report released?

    The most recent financial report for 訊聯 (1784) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 1784's short-term business performance and financial health. For the latest updates on 1784's earnings releases, visit this page regularly.

  • Where does 1784 fall in the P/E River chart?

    According to historical valuation range analysis, 訊聯 (1784)'s current price-to-earnings (P/E) ratio is 108.93, placing it in the Value zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of 1784?

    According to the latest financial report, 訊聯 (1784) reported an Operating Profit of -14.1M with an Operating Margin of -4.73% this period, representing a decline of 275.64% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 1784's revenue growth?

    In the latest financial report, 訊聯 (1784) announced revenue of 297.95M, with a Year-Over-Year growth rate of -1.96%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 1784 have?

    At the end of the period, 訊聯 (1784) held Total Cash and Cash Equivalents of 270.43M, accounting for 0.09 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 1784 go with three margins increasing?

    In the latest report, 訊聯 (1784) did not achieve the “three margins increasing” benchmark, with a gross margin of 54.98%%, operating margin of -4.73%%, and net margin of -2.12%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 1784's profit trajectory and future growth potential.

  • Is 1784's EPS continuing to grow?

    According to the past four quarterly reports, 訊聯 (1784)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 0.2. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 1784?

    訊聯 (1784)'s Free Cash Flow (FCF) for the period is -92K, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 99.91% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.